

Scott Kaatz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3870518/publications.pdf>

Version: 2024-02-01

99
papers

4,177
citations

236612

25
h-index

114278

63
g-index

99
all docs

99
docs citations

99
times ranked

5477
citing authors

#	ARTICLE	IF	CITATIONS
1	Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2015, 373, 823-833.	13.9	951
2	Comparison of Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control. <i>Archives of Internal Medicine</i> , 2007, 167, 239.	4.3	527
3	Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. <i>Lancet, The</i> , 2014, 383, 880-888.	6.3	425
4	Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 72-81.	1.0	362
5	Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. <i>American Journal of Hematology</i> , 2012, 87, S141-5.	2.0	320
6	Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. <i>American Journal of Hematology</i> , 2019, 94, 697-709.	2.0	225
7	Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia. <i>Annals of Internal Medicine</i> , 2019, 171, 153.	2.0	140
8	ISTH guidelines for antithrombotic treatment in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	1.9	100
9	Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 187-205.	1.0	93
10	Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. <i>American Journal of Medicine</i> , 2016, 129, 1001.e9-1001.e18.	0.6	69
11	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , 2018, 131, 2151-2160.	0.6	62
12	Determinants and measures of quality in oral anticoagulation therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 61-66.	1.0	55
13	Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. <i>Thrombosis Journal</i> , 2008, 6, 6.	0.9	44
14	Reversing factor Xa inhibitors – clinical utility of andexanet alfa. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 141-149.	0.7	44
15	Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2111788.	2.8	43
16	Variations in Peripherally Inserted Central Catheter Use and Outcomes in Michigan Hospitals. <i>JAMA Internal Medicine</i> , 2016, 176, 548.	2.6	42
17	Association of Adding Aspirin to Warfarin Therapy Without an Apparent Indication With Bleeding and Other Adverse Events. <i>JAMA Internal Medicine</i> , 2019, 179, 533.	2.6	37
18	COVID-19 versus HIT hypercoagulability. <i>Thrombosis Research</i> , 2020, 196, 38-51.	0.8	37

#	ARTICLE	IF	CITATIONS
19	Reversal of target-specific oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 195-202.	1.0	36
20	Patterns and Predictors of Peripherally Inserted Central Catheter Occlusion: The 3P-O Study. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 749-756.e2.	0.2	36
21	The Predictive Ability of the CHADS2 and CHA2DS2-VASc Scores for Bleeding Risk in Atrial Fibrillation: The MAQ12 Experience. <i>Thrombosis Research</i> , 2014, 134, 294-299.	0.8	35
22	Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. <i>JAMA Internal Medicine</i> , 2021, 181, 817.	2.6	33
23	Update in bridging anticoagulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 259-264.	1.0	30
24	Patterns and Predictors of Short-Term Peripherally Inserted Central Catheter Use: A Multicenter Prospective Cohort Study. <i>Journal of Hospital Medicine</i> , 2018, 13, 76-82.	0.7	29
25	Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 197-210.	1.0	29
26	Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents. <i>American Journal of Medicine</i> , 2016, 129, S80-S88.	0.6	23
27	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 283-288.	1.0	22
28	Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants. <i>Current Cardiology Reports</i> , 2017, 19, 124.	1.3	21
29	Barriers and facilitators to reducing frequent laboratory testing for patients who are stable on warfarin: a mixed methods study of de-implementation in five anticoagulation clinics. <i>Implementation Science</i> , 2017, 12, 87.	2.5	18
30	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.	0.6	18
31	Preclinical and clinical data for factor Xa and "universal" reversal agents. <i>American Journal of Emergency Medicine</i> , 2016, 34, 39-45.	0.7	16
32	Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice. <i>Thrombosis Research</i> , 2014, 134, 807-813.	0.8	14
33	Stroke Prevention in Patients With Atrial Fibrillation and Renal Dysfunction. <i>Stroke</i> , 2014, 45, 2497-2505.	1.0	13
34	Risk factors and outcomes associated with community-onset and hospital-acquired coinfection in patients hospitalized for coronavirus disease 2019 (COVID-19): A multihospital cohort study. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 1184-1193.	1.0	12
35	Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQ12) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. <i>Journal of Thrombosis and Thrombolysis</i> . 2018. 46, 316-324.	1.0	11
36	Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care. <i>International Journal of General Medicine</i> , 2015, 8, 283.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Surgical venous thromboembolism prophylaxis: clinical practice update. <i>Hospital Practice</i> (1995), 2020, 48, 248-257.	0.5	10
38	Bridging Anticoagulation Before Colonoscopy. <i>JAMA Cardiology</i> , 2016, 1, 1076.	3.0	9
39	Spontaneous Thyroid Hemorrhage on Chronic Anticoagulation Therapy. <i>Clinics and Practice</i> , 2017, 7, 932.	0.6	9
40	Missed opportunities to prevent upper GI hemorrhage: The experience of the Michigan Anticoagulation Quality Improvement Initiative. <i>Vascular Medicine</i> , 2019, 24, 153-155.	0.8	9
41	Contemporary NSTEMI management: the role of the hospitalist. <i>Hospital Practice</i> (1995), 2020, 48, 1-11.	0.5	9
42	Venous thromboembolism: What to do after anticoagulation is started. <i>Cleveland Clinic Journal of Medicine</i> , 2011, 78, 609-618.	0.6	9
43	Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. <i>Blood Advances</i> , 2017, 1, 2536-2540.	2.5	7
44	Rectus Sheath Hematoma Associated with Apixaban. <i>Clinics and Practice</i> , 2017, 7, 957.	0.6	7
45	Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 58-68.	1.0	7
46	“Reduce the Likelihood of Patient Harm Associated with the Use of Anticoagulant Therapy” Commentary from the Anticoagulation Forum on the Updated Joint Commission NPSG.03.05.01 Elements of Performance. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2020, 46, 173-180.	0.4	7
47	Use of apixaban and rivaroxaban in young adults with acute venous thromboembolism: a multi-center retrospective case series. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 844-848.	1.0	7
48	Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism. <i>Blood Advances</i> , 2022, 6, 4605-4616.	2.5	7
49	Venous Thromboembolism Prophylaxis After Hospital Discharge: Transition to Preventive Care. <i>Hospital Practice</i> (1995), 2011, 39, 7-15.	0.5	6
50	Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 566-572.	1.0	6
51	Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE. <i>Clinical Therapeutics</i> , 2017, 39, 1396-1408.	1.1	6
52	Periprocedural bridging anticoagulation in patients with venous thromboembolism: A registry-based cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2025-2030.	1.9	6
53	Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 500-505.	1.0	5
54	Comparison of temporary interruption with continuation of direct oral anticoagulants for low bleeding risk procedures. <i>Thrombosis Research</i> , 2021, 203, 27-32.	0.8	5

#	ARTICLE	IF	CITATIONS
55	A Multicenter Randomized Placebo Controlled Trial of Compression Stockings to Prevent the Post-Thrombotic Syndrome After Proximal Deep Venous Thrombosis: The S.O.X. Trial. <i>Blood</i> , 2012, 120, 393-393.	0.6	5
56	Impact of Early Corticosteroids on Preventing Clinical Deterioration in Non-critically Ill Patients Hospitalized with COVID-19: A Multi-hospital Cohort Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 887-898.	1.8	5
57	The changing characteristics of atrial fibrillation patients treated with warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 488-493.	1.0	4
58	Mind the gap: results of a multispecialty survey on coordination of care for peri-procedural anticoagulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 403-409.	1.0	4
59	COVID-19 risk index (CRI): a simple and validated emergency department risk score that predicts mortality and the need for mechanical ventilation. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 567-575.	1.0	4
60	Perioperative management of anticoagulation. <i>Hospital Practice (1995)</i> , 2020, 48, 231-240.	0.5	3
61	Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication. <i>Blood</i> , 2019, 134, 787-787.	0.6	3
62	Inflammation Markers and The Risk Of Post Thrombotic Syndrome: Results From The Bio-Sox Study. <i>Blood</i> , 2013, 122, 36-36.	0.6	3
63	Prediction of Bleeding Risk in Patients on Extended Oral Anticoagulation for Venous Thromboembolism. <i>Blood</i> , 2016, 128, 139-139.	0.6	3
64	Derivation and external validation of a simple risk score to predict in-hospital mortality in patients hospitalized for COVID-19. <i>Medicine (United States)</i> , 2021, 100, e27422.	0.4	3
65	Comparison of Patient Outcomes Before and After Switching From Warfarin to a Direct Oral Anticoagulant Based on Time in Therapeutic Range Guideline Recommendations. <i>JAMA Network Open</i> , 2022, 5, e2222089.	2.8	3
66	Impact on patient care: patient case through the continuum of care. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 167-170.	1.0	2
67	Reply to Letters Regarding Article, "Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial" <i>Circulation</i> , 2012, 125, .	1.6	2
68	Predictors Of The Post-Thrombotic Syndrome In a Large Cohort Of Patients With Proximal DVT: Secondary Analysis Of The Sox Trial. <i>Blood</i> , 2013, 122, 460-460.	0.6	2
69	Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients. <i>Blood</i> , 2016, 128, 144-144.	0.6	2
70	Perioperative consultative hematology: can you clear my patient for a procedure?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 521-528.	0.9	2
71	Association of adding antiplatelet therapy to warfarin for management of venous thromboembolism with bleeding and other adverse events. <i>Vascular Medicine</i> , 2022, 27, 382-384.	0.8	2
72	Top practice-changing articles over the last two years. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 325-332.	1.0	1

#	ARTICLE	IF	CITATIONS
73	Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. <i>Current Emergency and Hospital Medicine Reports</i> , 2014, 2, 76-89.	0.6	1
74	Discontinuation of Warfarin Therapy for Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 341.	3.0	1
75	Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2018, 34, 275-284.	0.9	1
76	Unprotected discharge: absence of stroke prevention strategies in patients with atrial fibrillation admitted for bleeding. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 62, 337-346.	0.6	1
77	Outcomes for Ximelagatran Compared with Warfarin According to INR Control: Results from SPORTIF III and V Atrial Fibrillation Trials.. <i>Blood</i> , 2005, 106, 902-902.	0.6	1
78	Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools.. <i>Blood</i> , 2010, 116, 3800-3800.	0.6	1
79	Perioperative Heparin Bridging in Patients Receiving Oral Anticoagulation: Meta-Analysis of Bleeding and Thromboembolic Rates. <i>Blood</i> , 2011, 118, 545-545.	0.6	1
80	A Comparison of Socioeconomic Factors in Patients Continuing Warfarin Versus Those Transitioning to Direct Oral Anticoagulants (DOACs) for Venous Thromboembolic Disease or Atrial Fibrillation. <i>Blood</i> , 2016, 128, 1179-1179.	0.6	1
81	Standard Versus Higher Intensity Anticoagulation for Patients With Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism. <i>American Journal of Cardiology</i> , 2021, 159, 100-106.	0.7	1
82	Diagnosis and Treatment of Venous Thromboembolic Disease. , 2013, , 755-764.		1
83	Duration of anticoagulation treatment in patients with venous thromboembolism. <i>Journal of the American Osteopathic Association</i> , The, 2010, 110, 638-44.	1.7	1
84	What you should know about the 2008 American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th) on Antithrombotic and Thrombolytic Therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 219-226.	1.0	0
85	New Oral Anticoagulants. <i>Hospital Medicine Clinics</i> , 2013, 2, e456-e471.	0.2	0
86	How to Develop and Validate Institutional ACS Protocols: Guidelines and Transitions of Care in ACS Management. <i>Current Emergency and Hospital Medicine Reports</i> , 2014, 2, 69-75.	0.6	0
87	Integrating Electronic Health Records in the Delivery of Optimized Anticoagulation Therapy. <i>Annals of Pharmacotherapy</i> , 2015, 49, 125-126.	0.9	0
88	CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge. <i>Current Medical Research and Opinion</i> , 2018, 34, 1967-1974.	0.9	0
89	Sarcoidosis presenting as facial and scalp ulceration with secondary bacterial infection of the skin. <i>BMJ Case Reports</i> , 2019, 12, e231769.	0.2	0
90	Treatment of Acute Venous Thromboembolism. <i>Medical Clinics of North America</i> , 2020, 104, 631-646.	1.1	0

#	ARTICLE	IF	CITATIONS
91	Leadership & Professional Development: Lessons Learned From the Other Side of the Stethoscope (and) Tj ETQq1 1,0,784314 rgBT /Ove	0.7	0
92	Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin for Elective Surger or Procedure - the BRIDGE Trial: Design, Rationale and Clinical Implications. Blood, 2011, 118, 4327-4327.	0.6	0
93	The Effectiveness Of 30-40 Mm Hg Compression Stockings To Treat Acute Leg Pain Associated With Proximal Deep Vein Thrombosis: Results From The Sox Randomized Controlled Trial. Blood, 2013, 122, 1126-1126.	0.6	0
94	Do Genetic Contributors to Warfarin Responsiveness or Common Thrombophilias Influence the Risk of Major Bleeding in Patients on Extended Duration Vitamin K Antagonist (VKA) for Venous Thromboembolic Disease?. Blood, 2016, 128, 272-272.	0.6	0
95	A Multi-Center Quality Improvement Intervention to Reduce the Inappropriate Use of Aspirin Among Patients Anticoagulated with Warfarin for Atrial Fibrillation or Venous Thromboembolism. Blood, 2019, 134, 788-788.	0.6	0
96	Extended Thromboprophylaxis in Patients with COVID-19. Blood, 2021, 138, 1065-1065.	0.6	0
97	Outcomes of Direct Oral Anticoagulants with Aspirin Versus Warfarin with Aspirin for Atrial Fibrillation and/or Venous Thromboembolic Disease. Blood, 2021, 138, 179-179.	0.6	0
98	Management Strategies Following Slightly Out of Range INRs: Watchful Waiting vs. Dose Changes. Blood Advances, 2022, , .	2.5	0
99	Ardeparin plus graduated compression stockings prevented DVT after knee surgery. ACP Journal Club, 1996, 125, 63.	0.1	0